Dermatology Malpractice Insurance in New York: A 2026 Cost, Carrier, and Melanoma-Tail Guide

TL;DR. Dermatology sits in the lower-middle band of New York's malpractice rate structure. At $1M/$3M claims-made limits, a NY dermatologist's annual premium typically runs about $6K to $20K depending on territory and procedure mix, well below OB/GYN and plastic surgery but above psychiatry. Two NY-specific exposures drive the planning: Lavern's Law extends the reporting tail on melanoma misdiagnosis cases to seven years, and Mohs surgery plus cosmetic-injectable crossover move the policy conversation from a general derm rider to a layered coverage stack that has to match the practice's actual service menu.

Why dermatology is a lower-cost specialty

Dermatology is one of the least expensive specialties to insure in New York, with 2024 National Practitioner Data Bank figures showing dermatology accounted for roughly 1.5 percent of US paid medical malpractice claims against about 1.4 percent of active physicians (NPDB Public Use Data File, 2024). Claim frequency sits near specialty parity, but severity runs well below surgical specialties because the dominant allegation pathways, misdiagnosis and cosmetic dissatisfaction, rarely produce the multi-million-dollar verdicts that drive orthopedic or OB/GYN pricing.

The severity profile that anchors derm pricing

Most dermatology claims fall into one of three allegation buckets. The largest, by frequency, is failure or delay to diagnose skin cancer, usually melanoma. The second is a cosmetic-outcome claim, where a patient alleges scarring, pigmentation change, asymmetry, or other aesthetic variance from a laser, peel, or cosmetic excision. The third is a product or medication reaction, typically to a prescribed topical, an injectable, or a light-based therapy. Melanoma misdiagnosis carries the largest single-case severity, but NY derm severity still sits below surgical specialties because the volume of high-dollar verdicts is lower.

How NY rates compare across specialties

At statewide base rates on $1M/$3M claims-made limits, psychiatry anchors the floor at roughly ~$13K–$16K, dermatology sits a step above in the ~$19K–$24K range, and internal medicine sits just above dermatology at about ~$29K–$32K before territory modifiers. General surgery runs in the low six figures, and OB/GYN and neurosurgery occupy the top of the NY rate grid at ~$170K–$200K and higher. The full cross-specialty context lives in our NY physician malpractice pillar guide.

The derm rate band is more compressed than most specialties, because the upside from a clean claim history is smaller in dollar terms than it is for a surgical specialty, but the downside from a single paid melanoma claim can move a dermatologist's renewal premium up a full tier. Risk-management investment for a NY dermatologist is less about reducing headline premium and more about keeping the paid-claim history clean enough to preserve admitted-market appetite. New York led the US in 2024 with $550.12M in malpractice payouts across 1,205 NPDB reports (Fiedler Deutsch / NPDB, 2024), and the no-damage-caps regime plus CPLR 214-a continuous-treatment doctrine lengthen effective reporting windows for every NY physician.

What does derm malpractice cost across New York zones?

NY dermatology premium runs roughly 3x between upstate and Long Island at standard $1M/$3M claims-made limits, with Manhattan and the outer boroughs sitting in the middle of the downstate range. The tail-coverage obligation, typically 150 to 200 percent of the final annual premium on termination, adds a five-figure one-time cost for any NY dermatologist with a downstate book. Mohs-heavy and cosmetic-heavy practices layer additional rider premium on top of the base, and the spread across procedure mixes is wide enough that two dermatologists on the same statewide base rate can produce quotes 40 percent apart at bind (NY Department of Financial Services rate filings, 2025).

Annual premium and tail estimate by region and procedure mix

Why Long Island and Brooklyn sit above Manhattan

Long Island carries the state's highest territory modifier because of Nassau and Suffolk County jury-verdict history, and Brooklyn typically prices above Manhattan because Kings County jury composition produces higher average verdicts. For dermatology, where most claims resolve well below the per-claim limit, the territory effect is less dramatic than for surgical specialties, but it still moves a cosmetic-heavy solo dermatologist's premium by $5K to $7K between Manhattan and Brooklyn addresses on identical books. Rochester and Buffalo territory modifiers run at roughly 0.5 to 0.7 against the downstate base. The borough math is covered in depth in our pillar-guide section on borough-level rate variance.

Procedure-mix relativities inside the derm code

Three procedure-mix layers move a derm quote inside the territory range. A general dermatology book weighted toward medical derm, skin-cancer screening, acne and psoriasis management, prices at the base range. A Mohs-heavy book adds rider premium reflecting surgical-reconstruction exposure, typically $2K to $5K on top of the base. A cosmetic-heavy book, weighted toward lasers, peels, injectables, and light-based therapy, prices at the upper end of each range because claim frequency on aesthetic-outcome allegations runs above the medical-derm average.

In our NY derm placements, the practices that price best on renewal are the ones that can produce a written procedure-mix breakdown by CPT code at submission, because underwriters can then apply the correct relativity rather than defaulting to the conservative top-of-range rating.

Carrier options: MLMIC, TDC, EmPRO, MedPro, and specialty writers

Five admitted carriers handle most NY dermatology placements, with a narrow surplus-lines backstop for the exposures that fall outside admitted appetite. MLMIC, the Berkshire Hathaway subsidiary insuring more than 13,000 NY physicians (MLMIC, 2024), is the volume writer. The Doctors Company carries the aesthetic unit that cosmetic-heavy derm practices often prefer. EmPRO, formerly PRI, with $190.2M in 2024 gross written premium and an 87.9% combined ratio (EmPRO results release, 2024), rounds out the NY-focused admitted market. MedPro and Indigo handle employed-physician and modern-platform placements respectively, and Hiscox writes smaller single-provider practices on a package basis.

MLMIC, TDC, and EmPRO on the admitted side

MLMIC writes NY dermatology as a straightforward specialty class, producing the territory-factor baseline against which every other carrier quotes. For a dermatologist without significant cosmetic or Mohs volume, MLMIC's base-times-territory math typically produces the most competitive quote. The carrier's appetite is cleanest for general derm and Mohs-inclusive practices, and its willingness to schedule cosmetic riders has broadened over the past several rate cycles. For a derm practice with an affiliated med spa, MLMIC's position on scheduling depends on physician-ownership structure and service-mix documentation. Our medical spa malpractice guide covers the mechanics.

TDC's aesthetic-surgery underwriting unit, consent-form library, and claims-handling experience on outcome-based cosmetic cases make it a frequent first-call for NY derm practices with meaningful cosmetic volume. TDC's cosmetic-relativity pricing is often tighter than MLMIC's for a laser and injectable-weighted book, and the carrier's willingness to schedule affiliated med spas on the physician policy is broader than most NY competitors. On general-derm-only books, MLMIC's leaner NY-specific rating usually wins.

EmPRO competes on service responsiveness, NY specificity, and a claims operation with long tenure on NY derm matters. EmPRO's derm book has expanded through recent rate cycles, and the carrier is often the price-leader on a clean mid-career submission in Westchester or the mid-Hudson.

MedPro, Indigo, Hiscox, and surplus lines

MedPro, a Berkshire Hathaway sibling to MLMIC, writes primarily employed dermatologists at multi-state groups and academic medical centers. For a solo or small-group NY dermatologist, MedPro is rarely the price-leader because its book tilts toward employed-physician placements. Indigo, a newer entrant with a modern broker-platform approach, has become a workable fourth bid on mid-career derm placements where the practice wants a tighter submission experience.

Hiscox writes smaller single-provider practices on a package basis, bundling professional liability, general liability, and sometimes cyber into a single product. The form is often cleaner than an admitted placement for a new practice without a multi-year loss history, and the practice graduates to MLMIC, TDC, or EmPRO once it matures. Surplus-lines markets, accessed through specialty wholesale brokers, pick up exposures outside admitted appetite: device-heavy practices, mid-level-heavy staffing models, newer operators, and practices with open claim reserves. E&S forms carry narrower claims definitions and no state-guaranty-fund backing.

A sensible NY dermatology submission runs simultaneously to MLMIC, TDC, and EmPRO on the admitted side, with MedPro added for employed-physician placements and Hiscox included for smaller practices. Our analysis of the best medical malpractice insurance options for NY physicians covers the broader carrier-selection framework.

Melanoma misdiagnosis and Lavern's Law: the seven-year tail

Dermatologists sit at the front of the melanoma diagnostic pathway, and NY's Lavern's Law amendment to CPLR 214-a resets the statute-of-limitations clock on cancer misdiagnosis claims to the date of discovery, capped at seven years from the alleged negligence (Lavern's Law overview, 2018). For dermatology, this is the single most consequential NY statutory exposure, because melanoma is often diagnosed years after the biopsy or monitoring decision a plaintiff will later allege was negligent.

What Lavern's Law actually changed

Before 2018, CPLR 214-a ran the NY malpractice clock from the date of the alleged act or the end of continuous treatment, on a 2-year-6-month window. A patient who learned of a missed cancer diagnosis three years later had no claim. Lavern's Law amended the statute to add a discovery rule for cancer and malignant-tumor cases: the clock now runs from the date the patient knew or reasonably should have known of the alleged negligence, with a seven-year backstop from the date of the underlying act.

For a dermatologist, this means a 2026 decision to monitor a suspicious mole rather than biopsy it can produce a claim window extending to 2033 if the patient is diagnosed with metastatic melanoma in 2030. The carrier reserving that policy year has to reserve for the full seven-year tail, which is one reason dermatology's tail factor often runs closer to 175 percent of annual premium than the 150 percent floor common to other low-severity specialties.

Why the reporting-tail period needs to match

A retiring NY dermatologist should buy a tail reporting period of seven years rather than the five-year standard that many employment contracts default to, and the tail-endorsement language should reference CPLR 214-a directly so future amendments to the statute track automatically. The gap between a five-year tail and the statutory window is two years of uninsured exposure for melanoma claims that surface after the tail expires. Physicians retiring after a downstate dermatology career can face personal-asset exposure on a post-tail melanoma claim well into seven figures.

Risk-management habits that keep admitted-market appetite intact

The NY dermatologists who keep the cleanest paid-claim histories share three documentation habits. First, they document the clinical reasoning for biopsy-versus-monitor decisions in the chart at the time of the encounter, not as a later addendum, referencing lesion morphology, ABCDE criteria, dermoscopy findings, and patient history. Second, they run a recall workflow that schedules follow-up visits for monitored lesions at defined intervals, tracked through the practice management system and escalated on missed appointments. Third, they photograph suspicious lesions at baseline and again at follow-up, with the photographs in the chart rather than on a separate imaging system. None of those practices costs meaningful money. Carriers ask about dermoscopy use, recall workflow, and photographic documentation at submission, and practices without written protocols on each see renewal quotes above the territory benchmark.

Mohs surgery and the surgical rider

Mohs micrographic surgery, the outpatient technique for excising non-melanoma skin cancers with margin-control precision, is covered under most NY dermatology malpractice policies when the dermatologist is fellowship-trained, credentialed to perform Mohs, and the procedure is scheduled on the policy. The American Society for Mohs Surgery and the American College of Mohs Surgery together track more than 2,600 fellowship-trained Mohs surgeons in the US, with New York among the top three states by active-practitioner count (ACMS member directory overview, 2024).

What carriers actually schedule and at what surcharge

MLMIC, TDC, and EmPRO each treat Mohs as part of the dermatologist's surgical scope rather than a separate specialty code. The rider shows up as a scheduled procedure on the declarations page, and the surcharge reflects severity tied to reconstructive-outcome, scarring, and recurrence allegations. A NY dermatologist with a modest volume of 100 to 200 cases per year typically sees a surcharge of about $2K to $3K annually. A Mohs-heavy practice at 400+ cases per year sees $4K to $6K. Fellowship training, case-volume documentation, and board certification in Mohs can earn schedule credits.

The rider does not typically cover reconstructive plastic surgery beyond closure of the Mohs defect itself. A dermatologist who performs complex flap reconstruction in-house should confirm whether the flap work is within the Mohs rider scope or requires a separate reconstructive endorsement. The distinction has surfaced as a coverage dispute in several recent NY claims.

Claim patterns and risk management

Three claim categories dominate Mohs malpractice in New York. First, inadequate margin control leading to recurrence, typically defensible when pathology and margin documentation are complete. Second, scarring and cosmetic-outcome allegations on facial-area cases, which settle more often because clinical causation is harder to dispute even when standard of care was met. Third, post-operative infection, hematoma, and wound dehiscence. Informed consent that specifically addresses expected cosmetic outcome, margin-related recurrence risk, and reconstructive options is the first-line defense. Intraoperative photography and complete margin-control documentation are the second-line defense when a claim lands.

Cosmetic procedure crossover and med-spa exposure

A NY dermatology practice that offers cosmetic injectables, laser treatments, chemical peels, microneedling, or body-contouring devices operates in two coverage worlds at once. The general dermatology professional liability policy covers the dermatologist's personal professional acts on cosmetic procedures performed within the practice's scope. A separately incorporated med spa, or a cosmetic program staffed by nurse practitioners or registered nurses under the dermatologist's supervision, often needs a distinct coverage structure that reflects NY's Corporate Practice of Medicine rules under Business Corporation Law §1503 and NY Education Law §6512.

When the practice policy covers the cosmetic work

A dermatologist who performs cosmetic procedures personally, as part of the same professional corporation that offers medical dermatology and within the scope of the dermatologist's medical license, is covered under the practice professional-liability policy. The cosmetic relativity inside the dermatology code applies, and the procedures are scheduled on the declarations in the same way as general derm procedures.

The coverage posture changes when the practice adds a separately incorporated entity or a staffing model where non-physician providers perform cosmetic procedures. NY's Corporate Practice rules require any entity that practices medicine to be owned by NY-licensed physicians, which means a dermatology-affiliated med spa that offers injectables, deeper laser, or FDA-regulated body-contouring devices must be structured as a physician-owned PC or PLLC, or as a management services organization where a physician owns the clinical entity and a separate MSO handles administration.

The three common structures for a derm-affiliated med spa

The simplest structure is the med spa operating as a division of the dermatologist's existing PC. The practice policy can be endorsed to add the division at a meaningful discount to a standalone entity policy. The second structure is a separate PC owned by the same dermatologist or MD partnership. The separate entity needs its own named-insured professional liability policy, and scheduling covers the physician's individual acts, the entity's vicarious liability, and any mid-level providers. The companion plastic surgery malpractice guide walks through the scheduling mechanics, and the medical spa malpractice guide covers the entity-level coverage stack.

The third structure is the MSO, where a dermatologist-owned PC holds the medical license and a separate business corporation or LLC handles non-clinical functions. A thinly structured MSO that directs clinical decisions or shares clinical revenue in a way that implicates fee-splitting rules under NY Education Law §6509-a can collapse into a Corporate Practice violation, which in turn triggers the scope-of-practice exclusion on the underlying malpractice policy and voids coverage for any claim tied to the non-compliant service.

The mid-level injector question

A NY dermatology practice staffing cosmetic injectables with an NP or RN under the dermatologist's supervision faces three coverage layers: the dermatologist's personal policy covers supervision acts, the entity policy covers the PC's vicarious liability, and the NP or RN needs either a named endorsement on the entity policy or a personal malpractice policy. MLMIC, TDC, and EmPRO each schedule NP and RN injectors on a derm practice's entity policy when supervision documentation is clean. Practices relying on medical assistants, cosmetologists, or unlicensed technicians to perform injectables are outside any NY-licensed scope, and the carrier decline is immediate. The scope violation triggers the unlicensed-practice exclusion on admitted-market forms, and the claim lands without defense.

Teledermatology and cross-state practice

Teledermatology expanded during the COVID-era flexibilities and has settled into a durable component of the NY dermatology coverage conversation. The underlying rule is straightforward: care delivered to a patient located in another state is practicing in that state, which means the dermatologist must be licensed in the patient's state and the malpractice policy must include the state on its scope of coverage. Standard NY admitted-market policies default to NY-only scope, and any cross-state telederm volume requires a state endorsement, a reciprocity-based multistate compact arrangement, or a separate policy.

Licensure and the Interstate Medical Licensure Compact

Physicians practicing telemedicine across state lines must be licensed in the state where the patient is located at the time of the encounter, under the rule that the practice of medicine occurs where the patient is. New York is not currently a member of the Interstate Medical Licensure Compact — IMLC enactment bills (S1505 / A1983) remained pending in the 2025-2026 NY legislative session as of this writing. NY-licensed dermatologists practicing teledermatology into IMLC member states therefore must apply for state-by-state licensure, not the compact pathway, and must hold the license in each state where patients are seen. A practice that cannot confirm the patient's physical location at the time of the encounter is exposed to unlicensed-practice allegations when an encounter occurs in a state where the physician is not licensed.

What the malpractice policy covers, and what it does not

A NY admitted-market professional liability policy defaults to NY-only scope. Cross-state telederm coverage requires either a state endorsement adding specific states, a nationwide scope endorsement subject to licensure, or a separate telederm-specific policy. MLMIC, TDC, and EmPRO each offer state-endorsement options, typically at a modest low-single-digit-thousands surcharge unless volume is substantial.

A claim arising from a telederm encounter in an unendorsed state can trigger the policy's scope-of-coverage exclusion and void defense. The exclusion operates independently of licensure status, which means a NY dermatologist licensed in New Jersey but whose policy does not include New Jersey on its scope is still uninsured for a New Jersey-based encounter. Both layers, licensure and policy scope, must be confirmed. Three documentation habits keep telederm encounters defensible: recording the patient's physical location at the start of each encounter, maintaining video or asynchronous-image quality records, and charting the standard of care applied plus any limitations the telederm modality imposed, with in-person follow-up instructions when indicated.

Tail economics for NY dermatology

Tail coverage, technically an extended reporting endorsement, typically costs 150 to 200 percent of the most recent annual claims-made premium for NY dermatology, paid as a single lump sum at policy termination. The specialty's relatively compressed premium range makes the absolute tail dollars more manageable than for a surgical specialty, but the Lavern's Law seven-year backstop and the melanoma-misdiagnosis reporting pattern mean the tail-period negotiation matters more than the tail-multiplier negotiation for a retiring dermatologist.

The 150 to 200 percent range and who pays

Industry-standard tail modeling uses a 200 percent multiplier as the planning ceiling. In actual NY dermatology quotes, the multiplier runs from about 150 percent for general-derm-only books with short claim-development profiles up to the full 200 percent for cosmetic-heavy and Mohs-heavy books. A Manhattan dermatologist at the upper end of the downstate range with a cosmetic-heavy book can face a tail obligation in the $30K to $45K range at retirement, a fraction of the six-figure tail that a downstate OB/GYN or plastic surgeon faces but still meaningful.

Tail responsibility is a contract term, not a coverage term. NY dermatology employment agreements follow one of three patterns: employer-paid, physician-paid, or split depending on who terminates. A fourth pattern, the free tail provision, waives the cost when termination follows retirement at a defined age, total permanent disability, or death. For a NY dermatologist negotiating a new contract, the two most useful asks are a free-tail trigger on retirement after age 55 with five years of continuous coverage, and a free-tail trigger on disability or death. Our deeper analysis of when tail coverage is required and how to price it walks through the contract language, and our piece on occurrence versus claims-made malpractice insurance in New York covers the structural alternative.

Career-stage timing and the seven-year tail

Because Lavern's Law extends the reporting window for melanoma misdiagnosis claims to seven years from the alleged negligence, a retiring NY dermatologist should buy a seven-year tail rather than the five-year standard. The seven-year window should be referenced in the tail endorsement by statute citation to CPLR 214-a so future amendments track automatically. A dermatologist winding down by stepping back from cosmetic and Mohs volume in the final policy year can reduce the premium base that drives the tail, proportionally lowering the tail dollar cost. The arithmetic only works with advance planning and an explicit carrier conversation about credential and scope documentation.

For broader context on the NY malpractice market that shapes every specialty's tail math, see our pillar guide on medical malpractice insurance in New York. Service-level information lives on the professional liability coverage page, and industry context for NY physicians sits on the physicians industry page.

Before you bind or renew

Dermatology malpractice in New York rewards practical structure: the right carrier on the submission for your procedure mix, the right cosmetic and Mohs riders scheduled at the correct procedure volume, the right mid-level and med-spa coverage if the practice has an affiliated cosmetic program, documented dermoscopy and recall workflows to preserve admitted-market appetite, and a tail reporting period that matches the Lavern's Law seven-year window on melanoma exposure. A 30-minute conversation with a broker appointed across MLMIC, TDC, EmPRO, MedPro, and Indigo, with surplus-lines access for any non-admitted pieces and NY healthcare counsel engaged separately on any Corporate Practice structure, is usually the most useful hour in the placement process. When you are ready, you can request a quote or schedule a consultation to walk through the specifics for your practice.